Retatrutide and Romance

Somewhere between a kale smoothie and a dopamine receptor, romance has reportedly filed for early retirement.

What the Funny People Are Saying about Love and Retatrutide

“Nothing kills a relationship faster than someone saying, ‘I’m not hungry… for anything.'” — Jerry Seinfeld

“I quit drinking once. Lost 10 pounds and three friends. Turns out people don’t like sober honesty.” — Ron White

“If a drug makes you lose weight and your boyfriend, that’s not a side effect, that’s a two-for-one special.” — Amy Schumer

The Drug That Ate Dinner… and Date Night

In a development that has startled scientists, confused couples, and delighted introverts everywhere, the experimental weight-loss drug Retatrutide — the so-called “Triple G” because it agonizes GLP-1, GIP, and glucagon receptors simultaneously — is now rumored to suppress not just appetite… but affection. It’s essentially Ozempic with commitment issues.

According to a recent report, users claim the drug has turned their emotional lives into something resembling a waiting room at the DMV: quiet, indifferent, and spiritually fluorescent. 🌿

One TikTok user described the experience as “not craving food or people anymore,” which doctors are calling “medically fascinating” and partners are calling “deeply inconvenient.” Relationship therapists, meanwhile, are calling their accountants.

Scientists Discover Love Was Just a Snack All Along

Researchers say the drug works by targeting the brain’s reward system, which is normally responsible for things like hunger, pleasure, and texting someone back within a reasonable timeframe. 🧠

Dr. Paul Kenny, a neuroscientist whose work on dopamine and addiction-like reward dysfunction laid the groundwork for this entire pharmaceutical adventure, described the situation as a “huge experiment,” which is exactly what you want to hear when your relationship depends on neurotransmitters behaving themselves. 🔬

Early theories suggest that if you dial down the brain’s reward signals, you don’t just stop craving pizza. You also stop craving Chad.

And once Chad is no longer neurologically rewarding, Chad becomes… just a guy who breathes loudly.

Couples Report New Era of “Mutual Indifference”

Relationship therapists are now seeing a surge in couples who describe their love life as “stable, calm, and completely unnecessary.”

One woman told reporters, “Before the drug, I thought my husband was my soulmate. Now he’s more like… a coworker I can’t fire.”

Her husband, who also takes the drug, responded, “That’s fair.”

Marriage counselors are calling this the first pharmaceutical breakthrough in achieving true emotional equality. Divorce attorneys are calling it a threat to revenue.

Pharmaceutical Companies Announce New Slogan

Insiders say drug companies are considering rebranding Retatrutide with a more honest slogan:

“Lose the weight. Lose the cravings. Lose Greg.”

An anonymous staffer leaked internal documents showing potential marketing campaigns:

• “Finally, a drug that helps you stop emotional eating and emotional dating.”
• “Side effects may include confidence, clarity, and suddenly realizing you don’t like your partner’s laugh.”

Eli Lilly’s stock analysts are reportedly divided between “this is a breakthrough” and “this ends badly at the SEC.” Both groups stopped caring about it sometime around Week 6 of the trial.

Experts Debate: Is This a Bug or a Feature?

Medical professionals are divided.

Some warn that emotional flattening, reduced libido, and even depression could be unintended side effects tied to dopamine disruption and hormonal changes — the same reward-blunting mechanism that makes french fries feel like cardboard apparently also makes candlelit dinners feel like HR meetings. 🕯️

Others argue that maybe, just maybe, the drug isn’t killing love…

…it’s revealing it.

Dr. Sophie Dix notes that the leap from “less food cravings” to “no romance” is scientifically questionable, pointing out that love is more complex than a single reward pathway. 🔬

Translation: If your relationship can be erased by a peptide, it may have already been hanging on by a shared Netflix password.

New Dating Trend: “GLP-1 Compatible”

Dating apps have already adapted.

Profiles now include:

• “6’1″, emotionally available, not currently on triple-agonist peptides.”
• “Looking for someone who still experiences joy.”
• “Must love dogs, long walks, and baseline serotonin levels.”

Meanwhile, a new app called Unbothered matches people who are equally uninterested in each other. It has a 94% retention rate because nobody could muster the dopamine to delete it.

The Rise of the Emotionally Efficient Human

Sociologists are calling this the dawn of a new archetype: the Emotionally Efficient Adult.

This person:

• Eats less
• Weighs less
• Feels less
• Texts back never

A recent poll found that 63% of users said they felt “calmer,” while 37% said they “forgot why they were dating someone in the first place but didn’t feel strongly enough to investigate.” (Margin of error: ± complete apathy)

Government efficiency advocates are said to be very interested in the data. Apparently running the Department of Labor on reduced dopamine is a feature, not a flaw.

Black Market Love vs. Black Market Peptides

Meanwhile, experts warn that Retatrutide is still in clinical trials and is already being sold through sketchy online channels, which is never a sentence that ends well. 💉

More than a third of these unregulated gray-market substances fail basic quality checks, meaning users may not even be receiving the correct compound. Forty-plus state attorneys general have formally flagged the problem, describing a “national ecosystem” of counterfeit peptides arriving from overseas and labeled, with stunning optimism, “for research purposes only.”

So not only might you lose your appetite and your partner…

You might also be injecting something that was labeled “definitely science.”

The Ultimate Relationship Question

At its core, this whole saga raises a profound philosophical question:

If a drug can make you stop loving someone…

Did you love them?

Or were you just… hormonally enthusiastic?

As one man reportedly said after starting the drug:

“I used to think she was the one. Now I think she’s… fine. Just fine.”

Historians confirm this is the least romantic sentence ever recorded. It has since been engraved on a Hallmark card that is moving surprisingly well in certain zip codes.

Final Thought: Love May Survive… But It’s on Notice

Scientists insist more research is needed — specifically, Phase 3 trials are still underway with FDA approval expected no earlier than late 2026 — and they’re probably right.

But until then, couples everywhere are left wondering:

Is it the drug…

or is it finally clarity?

Either way, candlelit dinners are being replaced with quiet mutual nods.

And honestly?

Some relationships have never been more peaceful. Or more legally defensible in small claims court.

Disclaimer: This satirical article is a collaborative effort between two highly questionable authorities: the world’s oldest tenured professor (who still thinks dopamine is a 90s boy band) and a philosophy major turned dairy farmer who once fell out of love with a sandwich. While inspired by real reporting, all interpretations, conclusions, and emotionally unavailable boyfriends are presented for comedic purposes only.

If you are currently in love, please consult your physician before dramatically reassessing your partner.

Auf Wiedersehen, amigo!

Retatrutide, developed by Eli Lilly under the research designation LY3437943, is an experimental “triple-G” drug currently in Phase 3 clinical trials that simultaneously activates GLP-1, GIP, and glucagon receptors — making it the most aggressive appetite-suppression compound yet tested. In Phase 2 trials, participants lost up to 24% of their body weight over 48 weeks, surpassing even semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro). Because GLP-1 receptors are also present in brain regions governing reward, motivation, and emotion — including the dopamine-producing ventral tegmental area — researchers including neuroscientist Dr. Paul Kenny have raised concerns that blunting the brain’s reward circuitry to suppress hunger may inadvertently suppress other pleasures. Anecdotal reports of reduced libido, emotional detachment, and diminished romantic feeling began circulating on social media in 2025, prompting renewed calls for comprehensive psychiatric monitoring in obesity drug trials. The drug is not yet FDA-approved; an approval decision is expected no earlier than late 2026.